Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: strong revenue growth and positive reception of nPulse, but increased non-GAAP costs and cash burn raise concerns. The strategic focus on partnerships and regulatory progress is promising, yet the lack of clear timelines for product releases and the decline in cash reserves temper optimism. The market may react cautiously, resulting in a neutral stock price movement.
Key Financial Performance
Total Revenue (Q4 2025) $264,000, up from $86,000 in Q3 2025. Sequential growth driven by both capital and disposable devices.
Cost of Product Revenue (Q4 2025) $260,000, slightly lower on a sequential basis compared to Q3 2025.
Total GAAP Costs and Expenses (Q4 2025) $18.5 million, decreased by $1.7 million compared to $20.3 million in the prior year period. Decrease driven by a reduction in nonrecurring expenses.
Total Non-GAAP Costs and Expenses (Q4 2025) $13.3 million, increased by $2 million compared to $11.3 million in the prior year period. Increase driven by clinical trial and early commercial launch activity.
GAAP Net Loss (Q4 2025) $17.4 million, compared to $19.4 million in the prior year period. Decrease attributed to reduced GAAP costs and expenses.
Non-GAAP Net Loss (Q4 2025) $12.2 million, compared to $10.4 million in the prior year period. Increase due to higher clinical trial and commercial launch activity.
Cash and Cash Equivalents (End of 2025) $80.7 million, compared to $118 million at the end of 2024. Decrease of $14.5 million versus Q3 2025, driven by operating activities.
Cash Used in Operating Activities (Q4 2025) $14.8 million, compared to $9.1 million in the prior year period and $13 million in Q3 2025. Increase reflects investment in pivotal trials, device scaling, and commercialization.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nanosecond Pulsed Field Ablation (nsPFA) Platform: Developed to shift medical treatment from extreme heat or cold to precise nanosecond pulsed field ablation. Offers precision, fast speeds, and a healing advantage. Added 67 issued and 77 pending patents in 2025, totaling 250 granted patents and 180 pending.
nPulse Cardiac Catheter System: World's first one-shot ablation solution for atrial fibrillation. Demonstrated 100% procedural success at 6 months and 96% at 1 year in European studies. CE Mark submission expected in 2026.
nPulse Vybrance Percutaneous Electrode System: Used for soft tissue ablation, particularly benign thyroid nodules. Generated $264,000 in Q4 revenue. Collaborating with MD Anderson Cancer Center for thyroid tumor treatment.
European Market Expansion: Expanded treatment of patients in European feasibility studies for cardiac platforms, generating robust data for CE Mark submission.
Strategic Partnerships: Actively pursuing partnerships with mapping providers and EP market leaders to accelerate global launch of nsPFA technology.
Clinical Development: Secured IDE approvals for electrophysiology catheter and cardiac surgical clamp programs. Progressing pivotal trials and European feasibility studies.
Financial Management: Maintained disciplined expense management with $80.7 million in cash and cash equivalents at year-end 2025. Filed a $200 million shelf registration for financial flexibility.
Focus on Electrophysiology and Cardiac Surgery: Prioritizing clinical and market development for atrial fibrillation treatment. Targeting CE Mark approvals and strategic partnerships.
Soft Tissue Ablation Expansion: Expanding clinical scope of Vybrance platform to include benign and malignant thyroid tumors. Collaborating with MD Anderson Cancer Center.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company is dependent on FDA indication clearance and CE Mark approval for its products. Delays or failures in obtaining these regulatory approvals could hinder market entry and revenue generation.
Clinical Trials: The success of the company's products relies heavily on the outcomes of ongoing and future clinical trials. Any unfavorable results or delays in these trials could impact the company's ability to commercialize its products.
Market Adoption: The company is taking a deliberate and limited approach to market adoption, which may slow revenue growth. Additionally, the need for evidence-based validation and reimbursement certainty could delay broader adoption.
Financial Sustainability: The company reported a net loss and is using significant cash for operations and clinical trials. While it has a strong balance sheet, continued losses could impact its ability to fund future activities.
Competitive Pressures: The company faces competition from existing ablation technologies and other emerging solutions. Failure to differentiate its products effectively could limit market share.
Supply Chain and Manufacturing: Scaling up device production and ensuring quality control are critical as the company moves toward commercialization. Any disruptions could delay product availability.
Strategic Partnerships: The company is pursuing strategic partnerships to accelerate market entry. Failure to secure these partnerships could slow commercialization and market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Clinical and Market Development Execution in 2026: Focus on commencing and completing enrollment in the nPulse cardiac catheter IDE study for electrophysiology, continuing European patient treatments to support CE Mark submission, and expanding IDE site activation for cardiac surgery. Aim to complete patient enrollment in 2026 and prepare for CE Mark submission by year-end.
Soft Tissue Ablation Development: Complete enrollment of the PRECISE benign thyroid nodule study, expand the study to 100 patients, deepen commercial utilization in key accounts, and demonstrate clinical advantages of the Vybrance nsPFA treatment. Plan to expand clinical scope to include malignant thyroid tumors in collaboration with MD Anderson Cancer Center.
European Feasibility Studies and CE Mark Submission: Use data from European feasibility studies to finalize CE submission for the nPulse cardiac catheter system in the second half of 2026, with potential CE Mark approval in 2027. File for CE Mark for the nPulse cardiac surgical clamp by the end of 2026.
Strategic Partnerships for Market Entry: Actively pursue strategic partnerships with mapping providers and EP market leaders to accelerate global commercial launch of nanosecond PFA technology.
Financial Guidance and Resource Allocation: Maintain disciplined expense management and ample liquidity to fund operations and clinical programs through major milestones in 2026. Recently filed a $200 million shelf registration to support balance sheet flexibility.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:When will Vybrance transition from limited release to broader release?
A:Vybrance is currently in a market development mode with a limited number of centers. The transition to broader release will depend on data-driven decisions, including quality outcomes, reimbursement acceleration, and FDA therapeutic indications. The company is focused on building a strong foundation before expanding commercialization.
Q:What is the status of the enrollment timelines for the post-market surveillance study for thyroid?
A:The enrollment is on track to be completed in the next 1 to 2 months. A majority of the patient target has already been enrolled, and the company plans to expand the study to increase the robustness of the data set.
Q:What has been the reception from the community regarding nPulse's performance at the AF Symposium?
A:The reception has been exceptionally positive, with significant buzz at the conference. The 96% procedural success rate and 90% freedom from arrhythmia at 1 year have garnered attention. The company plans to commence enrollment in the IDE study in the next 1 to 2 months and complete it in 2026.
Q:Are there any steps being made to make nPulse more effectively integrated with mapping systems like CARTO or EnSite?
A:Yes, improved software integration is expected in the IDE study. This integration could enhance lesion accuracy and potentially reduce the number of lesions required, improving procedural outcomes.
Q:What is the update on the next-generation nPulse system?
A:The next-generation nPulse system is still in development. It aims to integrate regional footprint ablation with a focal device in the same product, allowing for pulmonary vein isolation and left atrial ablation without device exchange.
Q:Are there any spillover benefits from nCLAMP to nPulse?
A:Yes, the benefits are derived from nsPFA technology. Data from nCLAMP and nPulse are being submitted to the FDA, providing more safety data and clarity on lesion delivery. These data sets are expected to support regulatory approvals.
Q:What are the hypotheses behind the clinical success rate of nPulse exceeding expectations?
A:The hypotheses include the unique mechanism of nsPFA energy, which provides consistent, deep, and transmural lesions. While preclinical experiments could assess other nerve targets, the company believes the clinical results are directly due to the energy delivered by nsPFA.
Q:What is the timing for future updates to the nPulse feasibility study results?
A:The next update will be at the HRS conference, with data presented based on the number of patients meeting endpoints by the cutoff deadlines. Enrollment in the IDE study is expected to commence in the next few months.
Q:What is the strategy for partnerships and funding?
A:The company is exploring partnerships, distribution, and other funding options. They have $80 million in the bank and additional potential from warrants. The focus is on achieving labels and reimbursement for Vybrance and nPulse, with significant progress expected in the next 4 to 8 quarters.
Q:Review of Unclear Management Responses
A:Management avoided providing specific timelines for the broader release of Vybrance, stating that it depends on data-driven decisions and building a strong foundation. Additionally, no specific timelines were given for the next-generation nPulse system, as it is still in development.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CE submission
PFA solution
ablation technology
activity
advantage
blood vessel
cancer
cell
class mapping
clearance
collaboration
decrease
disease
electrophysiology
heart
hospital
institution
isolation
manner
nPulse catheter
nanosecond PFA
nanosecond field
nature
nerve
nodule study
patent
physician catheter
potential tissue
precision
procedure time
property
research
set workflow
shot
speed
standard care
success
term
time system
world
PLSE Transcript
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral5-13
Pulse Biosciences, Inc. (PLSE) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call lacked substantial information on financial performance, strategic initiatives, or operational updates, leading to a neutral sentiment. The absence of clear guidance or significant announcements, combined with the acknowledgment of risks, does not indicate any strong market movement. Without explicit financial metrics or strategic developments, the stock price is unlikely to experience significant volatility.
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Unknown2-20
The earnings call reveals mixed signals: strong revenue growth and positive reception of nPulse, but increased non-GAAP costs and cash burn raise concerns. The strategic focus on partnerships and regulatory progress is promising, yet the lack of clear timelines for product releases and the decline in cash reserves temper optimism. The market may react cautiously, resulting in a neutral stock price movement.
PLSE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
